CTOs on the Move

Hospital Physician Partners

www.hppartners.com

 
As one of the largest and fastest-growing Emergency and Hospital Medicine groups in the nation, we partner with more than 5,000 world-class providers who treat more than 6 million patients annually. Physician-led, our team consists of motivated, personable, highly qualified people interested in putting the patient first. We’re committed to doing the right thing for the patients, physicians, and hospitals we serve. Which is why 98% of our physicians recommend us to colleagues and friends. William C. Schumacher, M.D., a board certified emergency medicine physician, formally founded the Schumacher Group in 1994. The philosophy behind Schumacher Group`s founding was based ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Clinique Laboratories, LLC

Clinique Laboratories, LLC is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New York, NY. To find more information about Clinique Laboratories, LLC, please visit www.clinique.com

MedComm Solutions

MedComm Solutions is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paradigm Medical Industries

Paradigm Medical Industries is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genetics and IVF Institute

Genetics and IVF Institute is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Genetics and IVF Institute is based in Fairfax, VA. You can find more information on Genetics and IVF Institute at www.givf.com

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.